ArticlesArchiveAboutEditorial BoardAuthor Guidelines
Call for papersThe 2026 special issue on Climate & Health is open for submissions.Learn more
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En…
Sensuke Konno, Bobby Alexander, Drew Freilich, Muhammad Choudhury
Although chemotherapy is one of several therapeutic options for cancer patients, the outcomes have been less satisfactory with palpable side effects in many cases. To help improve the efficacy of chemotherapy, we examined whether D-fraction (DF), a bioactive…
Kalyan J. Gangavarapu, Alok Bhushan, James C. K. Lai, Christopher K. Daniels
Interleukin-6 (IL6)-triggered JAK/STAT3 and PI3K/AKT signaling pathways are known to mediate cell survival, drug resistance and progression in a variety of cancer cells. Resistance to induction of apoptosis plays a critical role in the pathogenesis of numerou…
Thomas Pletschko, Sheena Gmoser, Linda Leeb, Agathe Schwarzinger, Irene Slavc, Ulrike Leiss
Survivors of pediatric central nervous system (CNS) cancer are at risk for long term sequelae concerning school par ticipation. Therefore, the purpose of the study was to develop and evaluate a school-participation questionnaire for pa tients and parents base…
Kelly Leleux, Tri Pham, Mya Davis, Priya Karmali, Hector Biliran
Pancreatic cancer is a highly aggressive disease with a very high mortality rate among all human cancers. The poor prognosis is in part due to intrinsic resistance to the apoptosis-inducing effects of radio- and chemotherapy. To find al ternative cell death p…
Zhiguo Luo, Qian Wang, Wei Peng, Jianhua Chang, Xichun Hu, Xiaonan Hong
Introduction : For patients with anthracycline - resistant metastatic angiosarcoma, currently there is no available stan dard for second-line therapy and there is a need for novel effective regimens to improve response rates. Case report : We reported here ab…
Parminder Singh, Amit. M. Algotar, Erika R. Bracamonte
Prostatic small cell carcinoma (PSCC) is a distinct clinical phenotype of prostate cancer. Although rare, this phenotype is highly aggressive with very high mortality. Due to this, it is imperative for clinicians to be aware of it, diagnose it early and treat…
Dominic E. Sanford, Matthew R. Porembka, Roheena Z. Panni, Jonathan B. Mitchem, Brian A. Belt, Stacey M. Plambeck-Suess, Goldie Lin, David G. DeNardo, Ryan C. Fields, William G. Hawkins, Steven M. Strasberg, Craig Lockhart, Andrea Wang-Gillam, Simon Peter Goedegebuure, David C. Linehan
Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy characterized by abundant granulocytic myeloid-derived suppressor cells (G-MDSC = CD45 + /Lin ﹣ /CD33 + /CD11b + /CD15 + ), which infiltrate tu mors and suppress anti-tumor immuni…
Huaquan Wang, Xianghong Chen, Erika A. Eksioglu, Junmin Zhou, Nicole R. Fortenbery, Julie Djeu, Alan List, Sheng Wei
Multiple myeloma (MM) is a plasma cell neoplasm characterized for its fast evolution and for being practically incurable, presenting a strong need for the development of therapies to target it. Among those under study are lenalidomide and arsenic trioxide (AT…
Liesl K. Jeffers, Kaiwen Duan, Lesley G. Ellies, William T. Seaman, Raquel A. Burger-Calderon, Luda B. Diatchenko, Jennifer Webster-Cyriaque
Although metastasis-associated lung adenocarcinoma transcript (MALAT)-1 is known to be consistently upregulated in several epithelial malignancies, little is known about its function or regulation. We therefore examined the relationship between MALAT-1 expres…
Camilleri Gail, Borg Grima Karen, Zarb Francis
Over the past two decades, the sentinel lymph node biopsy (SLNB) based on sentinel node (SN) being the first lymph node that harbors metastases, revolutionized breast cancer management. SLNB presents much less morbidity when compared to radical axillary lymph…
No articles in this issue.
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En… All articles are open access under a CC BY 4.0 licence, with authors retaining copyright.
Authors submit their manuscript, metadata, and declarations through the portal. There is no submission fee.
The editorial office screens the manuscript for scope, completeness, and formatting before assigning a handling editor.
At least two independent reviewers evaluate the manuscript under single-blind review. Where revisions are required, authors respond point by point.
On acceptance the article processing charge is invoiced and the CC BY 4.0 copyright handover is signed.
The article is copyedited, typeset, and given a DOI, then publishes open access with a permanent link.
Manuscripts must be original and not under consideration elsewhere. Submit in Microsoft Word or LaTeX with figures at 300 dpi minimum. Structure research articles as Abstract, Introduction, Methods, Results, Discussion, and References.
Use the journal's numbered (Vancouver) reference style. Cite sources consecutively in the order they appear, and ensure every reference is complete and retrievable.
Declare all funding sources, conflicts of interest, and ethical approvals (including informed consent and animal-care statements where applicable).